EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond

Zishan Yang, Bingjun Ha, Qinhan Wu, Feng Ren, Zhinan Yin, Hongru Zhang

Frontiers in Immunology · 19.02.2025 · 16

DOI: 10.3389/fimmu.2025.1544532 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 19.02.2025. Verfasst von Zishan Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Xinxiang Key Laboratory of Tumor Vaccine and Immunotherapy, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Autoimmune Diseases, Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)-T-cell therapy has garnered significant attention for its transformative impact on the treatment of hematologic malignancies such as leukemia and lymphoma. Despite its remarkable success, challenges such as resistance, limited efficacy in solid tumors, and adverse side effects remain prominent. This review consolidates recent advancements in CAR-T-cell therapy and explores innovative engineering techniques and strategies to overcome the immunosuppressive tumor microenvironment (TME). We also discuss emerging applications beyond cancer, including autoimmune diseases and chronic infections. Future perspectives highlight the development of more potent CAR-T cells with increased specificity and persistence and reduced toxicity, providing a roadmap for next-generation immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveAutoimmune DiseasesReceptors, Chimeric AntigenNeoplasmsT-LymphocytesHumansTumor MicroenvironmentAnimalsReceptors, Antigen, T-Cell

Stichwörter der Autor:innen

CAR-T cellsadoptive immunotherapyautoimmune diseasessolid tumorstumor microenvironment

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Xinxiang Key Laboratory of Tumor Vaccine and Immunotherapy, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, Henan, China.
  • Henan International Joint Laboratory of Immunity and Targeted Therapy for Liver-Intestinal Tumors, Xinxiang Medical University, Xinxiang, Henan, China.
  • State Key Laboratory of Medicinal Chemical Biology, Tianjin Key Laboratory of Protein Sciences, Cancer Biology Center, College of Life Sciences, Nankai University, Tianjin, China.
  • Zhuhai Precision Medical Center, Zhuhai People's Hospital (Zhuhai Hospital Affiliated with Jinan University), Jinan University, Zhuhai, Guangdong, China.
  • The Biomedical Translational Research Institute, Jinan University, Guangzhou, Guangdong, China.
  • Nankai International Advanced Research Institute (Shenzhen Futian), Nankai University, Shenzhen, Guangdong, China.

Zitieren

APA

Yang, Z., Ha, B., Wu, Q., Ren, F., Yin, Z., & Zhang, H. (2025). Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1544532

Vancouver

Yang Z, Ha B, Wu Q, Ren F, Yin Z, Zhang H. Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond. Frontiers in Immunology. 2025;16. doi:10.3389/fimmu.2025.1544532

BibTeX
@article{Yang2025,
  author = {Yang, Zishan and Ha, Bingjun and Wu, Qinhan and Ren, Feng and Yin, Zhinan and Zhang, Hongru},
  title = {Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond},
  journal = {Frontiers in Immunology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fimmu.2025.1544532}
}
Kostenlos starten →